Skip to Main Content

Paper Details

Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial.
JNCI Cancer Spectr
11
2022
Author NameAffiliation
Gerhardt AttardUCL Cancer Institute
  • 1 - 1

Datasets

Release 1.2